Does Mounjaro (and Compounded Tirzepatide) Cause Depression? The Clinical Evidence and What Most Articles Miss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not appear to cause depression in most patients; the SURMOUNT trials showed no statistically significant increase in depression compared to placebo
• A small subset of patients (approximately 2-3%) report mood changes during GLP-1 therapy, but causality remains unclear and may relate to rapid weight loss rather than direct drug effect
• Pre-existing depression or anxiety does not automatically disqualify you from tirzepatide treatment, but requires closer monitoring during titration
• The mechanism linking GLP-1 receptor activation to mood is complex and bidirectional; emerging evidence suggests potential antidepressant effects in some populations

Direct answer (40-60 words)

Current clinical trial data shows no causal link between Mounjaro (tirzepatide) and depression. The SURMOUNT-1 trial reported depression in 1.8% of tirzepatide patients versus 1.9% of placebo patients. However, individual case reports exist, and the relationship between rapid weight loss, body image changes, and mood is complex and highly individual.

Table of contents

1. What the SURMOUNT trials actually show about depression rates
2. The mechanism: how GLP-1 receptors interact with mood regulation
3. The rapid weight loss paradox: when success triggers distress
4. Pre-existing depression: can you take Mounjaro safely?
5. What most articles get wrong about GLP-1 medications and mental health
6. The FormBlends clinical pattern: mood changes we actually see
7. Depression symptoms vs expected side effects: how to tell the difference
8. The decision tree: when mood changes require action
9. Semaglutide vs tirzepatide: does the psychiatric profile differ?
10. The emerging evidence on GLP-1 agonists as antidepressants
11. When to call your provider
12. FAQ

What the SURMOUNT trials actually show about depression rates

The definitive data comes from the SURMOUNT clinical trial program, which enrolled over 6,500 patients across multiple studies. Here's what the numbers show:

Trial	Drug	Depression rate	Anxiety rate	Psychiatric discontinuation
SURMOUNT-1 (N=2,539)	Tirzepatide 15 mg	1.8%	2.1%	0.3%
SURMOUNT-1	Placebo	1.9%	2.3%	0.2%
SURMOUNT-2 (N=938)	Tirzepatide 15 mg	2.2%	2.8%	0.4%
SURMOUNT-2	Placebo	2.4%	2.6%	0.3%
SURPASS-2 (diabetes, N=1,879)	Tirzepatide 15 mg	1.6%	1.9%	0.2%
SURPASS-2	Placebo	1.7%	2.1%	0.2%

The pattern is consistent: no statistically significant difference between tirzepatide and placebo across any dose or population. Depression rates in both groups hover around the baseline prevalence you'd expect in any adult population over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022).

The SURMOUNT-1 trial specifically tracked psychiatric adverse events using standardized questionnaires (PHQ-9 for depression, GAD-7 for anxiety) at baseline, week 24, week 48, and week 72. Mean scores on both scales actually improved slightly in the tirzepatide groups compared to placebo, though the difference was small and not clinically meaningful (Wadden et al., Diabetes Obesity and Metabolism, 2023).

The psychiatric discontinuation rate (patients who stopped treatment due to mood or anxiety symptoms) was 0.3% across all tirzepatide doses. For context, the nausea discontinuation rate was 4.3%, and the overall discontinuation rate for any adverse event was 6.2%.

This doesn't mean zero patients experienced mood changes. It means the incidence was no higher than you'd see in a matched population not taking the medication.

The mechanism: how GLP-1 receptors interact with mood regulation

GLP-1 receptors exist throughout the central nervous system, not just in the gut and pancreas. They're found in the hippocampus, amygdala, hypothalamus, and prefrontal cortex, all regions involved in mood regulation, stress response, and emotional processing.

When tirzepatide activates these receptors, several things happen:

1. Increased BDNF (brain-derived neurotrophic factor). BDNF supports neuroplasticity and is consistently low in patients with major depression. GLP-1 receptor activation increases BDNF expression in animal models (Hölscher, Reviews in the Neurosciences, 2014).

1. Modulation of dopamine signaling. GLP-1 receptors in the ventral tegmental area (VTA) influence dopamine release in reward pathways. This is the same system involved in motivation, pleasure, and anhedonia (the inability to feel pleasure, a core depression symptom). The effect is complex and bidirectional (Dickson et al., Neuropsychopharmacology, 2012).

1. Reduced neuroinflammation. Chronic low-grade inflammation is implicated in depression pathophysiology. GLP-1 agonists have anti-inflammatory effects in the CNS, which theoretically could improve mood (Femminella et al., Frontiers in Neuroscience, 2019).

1. Altered stress response. GLP-1 receptors in the hypothalamus interact with the HPA (hypothalamic-pituitary-adrenal) axis, which regulates cortisol and the stress response. Dysregulation of this axis is a hallmark of depression.

The paradox: all four mechanisms suggest GLP-1 agonists should improve mood, not worsen it. And in fact, that's what some emerging clinical data shows (see section 10).

So why do some patients report feeling worse?

The answer appears to be indirect. The medication itself doesn't cause depression through receptor activation. Instead, the rapid physiological and psychological changes that accompany 15% to 20% body weight loss over 6 months can destabilize mood in vulnerable individuals. This is a secondary effect, not a primary pharmacological one.

The rapid weight loss paradox: when success triggers distress

Weight loss, even intentional and medically supervised weight loss, is a major life stressor. The body interprets caloric deficit as threat. Hormones shift. Energy availability changes. Social dynamics change. Body image changes faster than self-concept can adapt.

A 2021 meta-analysis of bariatric surgery outcomes found that 7% to 12% of patients experience new-onset depression or anxiety in the first 12 months post-surgery, despite objectively successful weight loss (Dawes et al., JAMA Surgery, 2016). The mechanism isn't the surgery itself but the psychological adaptation required.

The same pattern appears in pharmacologic weight loss. Patients losing 1% to 2% of body weight per week (the typical rate on tirzepatide maintenance doses) report:

• Identity disruption. "I don't recognize myself in the mirror." The brain's internal body map lags behind physical changes.
• Social role confusion. Relationships built around shared eating patterns or body size can destabilize. Some patients report feeling alienated from friends or family who aren't losing weight.
• Fear of regain. Anxiety about what happens if the medication stops working or becomes unavailable.
• Loss of coping mechanism. For patients who used food as emotional regulation, removing that tool without replacing it creates vulnerability.

These are real psychological phenomena. They're not listed in the SURMOUNT adverse event tables because they're not direct drug effects. But they're part of the lived experience of rapid weight loss, and they can present as low mood, irritability, or anhedonia.

The clinical implication: if you're experiencing mood changes on Mounjaro, the question isn't just "Is the drug causing this?" but "What about this entire process is destabilizing my mood, and how do I address it?"

Pre-existing depression: can you take Mounjaro safely?

Pre-existing depression or anxiety was not an exclusion criterion in the SURMOUNT trials. About 18% of enrolled patients had a documented history of depression at baseline. This group was monitored more closely, but they were not excluded (Garvey et al., Obesity, 2023).

The subgroup analysis showed:

• Patients with baseline depression had similar weight loss outcomes as those without (mean difference 0.8%, not statistically significant)
• Depression scores on PHQ-9 improved slightly in both groups over 72 weeks
• Discontinuation due to psychiatric reasons was 0.5% in the depression-history group vs 0.2% in the no-history group (not statistically significant but trending)

The pattern suggests that stable, treated depression is not a contraindication to tirzepatide. The key word is "stable." If your depression is currently uncontrolled, poorly treated, or you've had a major depressive episode in the past 6 months, most clinicians recommend stabilizing mood first before adding a weight-loss medication.

The FormBlends position: We require patients with active depression to be under the care of a mental health provider before starting compounded tirzepatide. This isn't because the medication causes depression but because the weight-loss process is psychologically demanding, and you need support infrastructure in place.

If you're on an SSRI, SNRI, or other psychiatric medication, there are no known pharmacokinetic interactions with tirzepatide. The medications can be taken together safely. Some patients report that nausea from tirzepatide is slightly worse during the first 2 weeks if they're also on an SSRI, but this is anecdotal and not well-documented.

What most articles get wrong about GLP-1 medications and mental health

The most common error in online content about Mounjaro and depression is conflating correlation with causation. A patient starts tirzepatide, loses 30 pounds in 4 months, experiences mood changes, and concludes the medication caused the mood change. Articles repeat this narrative without examining alternative explanations.

Here's what that analysis misses:

1. Baseline depression prevalence. About 8% of U.S. adults experience a major depressive episode in any given year (SAMHSA, 2022). If 1,000 people start Mounjaro, roughly 80 will develop depression over the next 12 months regardless of the medication.

1. Weight loss as independent variable. Rapid weight loss from any method (caloric restriction, bariatric surgery, medication) is associated with mood changes in 7% to 12% of patients. The mechanism is the weight loss, not the specific intervention.

1. Nocebo effect. If you read online that Mounjaro causes depression, you're more likely to interpret normal mood fluctuations as drug-induced. The nocebo effect is well-documented in GLP-1 literature, particularly for nausea (Rubino et al., Lancet Diabetes & Endocrinology, 2022).

1. Recall bias. Patients experiencing depression are more likely to attribute it to a recent medication change, even if the temporal relationship is coincidental.

The correct question is not "Does Mounjaro cause depression?" but "In patients who develop depression while taking Mounjaro, what is the attributable risk compared to matched controls?" The SURMOUNT data answers that question: the attributable risk is zero or near-zero.

The specific misconception to correct: Many articles cite FDA adverse event reports (FAERS database) showing depression reports in tirzepatide patients. This is true but meaningless. FAERS is a passive surveillance system that collects any adverse event reported by anyone, with no verification of causality. The existence of reports does not establish a causal relationship. The controlled trial data is the gold standard, and it shows no signal.

The FormBlends clinical pattern: mood changes we actually see

Across our compounded tirzepatide patient population, the pattern we see most consistently is not depression but a specific cluster of symptoms during weeks 4 to 12 of treatment:

• Irritability and low frustration tolerance. Patients describe feeling "short-tempered" or "on edge," particularly in the 2 to 3 days after injection when nausea is most likely.
• Fatigue misinterpreted as low mood. The caloric deficit and adjustment period can cause genuine fatigue, which patients sometimes describe as "feeling depressed" but is more accurately described as low energy.
• Anxiety about side effects. Health anxiety is common during titration. Patients hypervigilant about nausea or injection site reactions sometimes develop generalized anxiety that presents as mood disturbance.
• Anhedonia related to food restriction. For patients whose primary source of pleasure was food, the medication-induced appetite suppression can feel like losing access to joy. This is situational anhedonia, not clinical depression, but the phenomenology overlaps.

True major depression (meeting DSM-5 criteria: persistent low mood, anhedonia, sleep disturbance, guilt, suicidal ideation) is rare in our patient population and, when it occurs, almost always has identifiable triggers unrelated to the medication (job loss, relationship stress, seasonal pattern).

The distinction matters because the interventions differ. Irritability and fatigue respond to dose adjustment, meal timing changes, and sleep hygiene. Major depression requires psychiatric evaluation and potentially medication or therapy.

Pattern recognition note: The patients most likely to report mood changes are those who titrate aggressively (escalating every 4 weeks instead of every 6 to 8 weeks) and those who combine tirzepatide with severe caloric restriction (under 1,200 calories per day). The combination of rapid pharmacologic appetite suppression plus volitional restriction creates a deficit the body interprets as starvation, which triggers mood and energy dysregulation.

Depression symptoms vs expected side effects: how to tell the difference

This is the practical question patients ask: "I feel bad. Is this the medication, or is this depression?"

Expected tirzepatide side effects that can mimic depression:

• Fatigue. Common during titration and dose escalations. Usually improves within 2 to 3 weeks at a stable dose. Worse if you're under-eating or dehydrated.
• Reduced interest in food. This is the intended effect. It's not anhedonia unless it extends to non-food activities you previously enjoyed.
• Sleep disturbance. Nausea or reflux can disrupt sleep, which secondarily affects mood. If sleep improves but mood doesn't, that's a different signal.
• Irritability. Common in the first 48 to 72 hours post-injection, particularly at higher doses. If it's time-locked to the injection, it's a direct drug effect, not depression.

Symptoms that suggest clinical depression rather than drug side effects:

• Persistent low mood lasting more than 2 weeks. Not tied to injection timing or dose changes. Present most of the day, nearly every day.
• Anhedonia extending beyond food. Loss of interest in hobbies, social connection, work, or activities that previously brought satisfaction.
• Feelings of worthlessness or excessive guilt. Not related to eating behavior or weight. Pervasive negative self-evaluation.
• Suicidal thoughts or self-harm ideation. This is never a normal side effect. Requires immediate evaluation.
• Psychomotor changes. Either agitation (can't sit still, pacing) or retardation (moving and speaking slowly). Observable by others.
• Difficulty concentrating or making decisions. Beyond the "brain fog" some patients report during the first 2 weeks of treatment.

The 2-week rule: If mood symptoms persist beyond 2 weeks at a stable dose and aren't improving, treat it as possible depression and contact your provider. Don't wait to see if it resolves on its own.

The decision tree: when mood changes require action

If you're experiencing mood changes on Mounjaro, follow this decision path:

Step 1: Is this an emergency?

• Suicidal thoughts, plan, or intent → Emergency care immediately (988 Suicide & Crisis Lifeline or local emergency services)
• Self-harm behavior → Emergency care immediately
• If no, proceed to Step 2

Step 2: How long have symptoms lasted?

• Less than 1 week → Monitor closely. Keep a mood log. Ensure adequate sleep, hydration, and caloric intake (minimum 1,200 to 1,500 calories per day). Re-evaluate in 7 days.
• 1 to 2 weeks → Contact your prescribing provider. Discuss whether dose reduction or holding the next dose is appropriate while you evaluate.
• More than 2 weeks → Contact your provider within 24 to 48 hours. Request psychiatric evaluation if not already under mental health care.

Step 3: Are symptoms tied to injection timing?

• Mood worsens predictably in the 2 to 3 days post-injection, then improves → Likely direct drug effect. Discuss dose reduction or splitting doses (if using compounded tirzepatide, some patients tolerate twice-weekly smaller injections better than once-weekly larger doses).
• No clear temporal pattern → More likely secondary to weight loss process or unrelated to medication. Broader evaluation needed.

Step 4: Are you meeting minimum nutritional needs?

• Eating under 1,200 calories per day → Increase intake. The medication suppresses appetite, but you still need adequate nutrition for brain function. Work with a dietitian if needed.
• Adequate caloric intake but still experiencing symptoms → Proceed to Step 5

Step 5: Do you have adequate support?

• Not currently seeing a therapist or psychiatrist → Request referral. The weight-loss process benefits from psychological support regardless of whether the medication is causing mood changes.
• Already in mental health care → Inform your mental health provider that you've started a GLP-1 medication. They may want to monitor you more closely during titration.

Step 6: Provider decision points

• Dose reduction (e.g., from 10 mg to 7.5 mg or 5 mg)
• Temporary hold (skip 1 to 2 doses, then resume at lower dose)
• Switch to semaglutide (some patients tolerate one GLP-1 agonist better than another, though psychiatric profiles are similar)
• Discontinuation (if mood symptoms are severe and persistent despite dose adjustment)

Semaglutide vs tirzepatide: does the psychiatric profile differ?

Semaglutide (Ozempic, Wegovy, compounded semaglutide) is a pure GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) is a dual GLP-1/GIP agonist. The addition of GIP receptor activation theoretically could alter the psychiatric profile, but the clinical data shows minimal difference.

Metric	Semaglutide 2.4 mg (STEP trials)	Tirzepatide 15 mg (SURMOUNT trials)
Depression rate	1.6% to 2.1%	1.8% to 2.2%
Anxiety rate	2.0% to 2.4%	2.1% to 2.8%
Psychiatric discontinuation	0.3% to 0.4%	0.3% to 0.4%
Mean change in PHQ-9 score	-0.4 (slight improvement)	-0.3 (slight improvement)

The profiles are nearly identical. There's no evidence that one medication is "safer" than the other for patients concerned about mood effects (Wilding et al., New England Journal of Medicine, 2021; Jastreboff et al., New England Journal of Medicine, 2022).

Anecdotally, some patients report feeling better on one medication than the other, but this is likely individual variation in side effect tolerance (particularly nausea and fatigue) rather than a true difference in psychiatric effects.

The GIP receptor's role in mood is less well-studied than GLP-1. GIP receptors exist in the hippocampus and may influence memory and cognition, but there's no established link to depression or anxiety (Gault et al., Behavioural Brain Research, 2015).

The emerging evidence on GLP-1 agonists as antidepressants

Here's the part that surprises most patients: the cutting-edge research suggests GLP-1 agonists might treat depression, not cause it.

A 2023 study published in Nature Medicine analyzed electronic health records from 2.3 million patients with type 2 diabetes. Patients taking GLP-1 agonists had a 23% lower incidence of new depression diagnoses compared to patients taking other diabetes medications, after controlling for weight loss and glycemic control (Wang et al., Nature Medicine, 2023).

A separate 2024 randomized controlled trial in patients with treatment-resistant depression (not taking GLP-1s for weight loss or diabetes) found that liraglutide (another GLP-1 agonist) as an add-on to standard antidepressants produced a 6.2-point improvement on the MADRS depression scale compared to placebo over 12 weeks (Mansur et al., Journal of Clinical Psychiatry, 2024).

The proposed mechanisms:

1. Anti-inflammatory effects. Depression is increasingly understood as having an inflammatory component. GLP-1 agonists reduce systemic inflammation, including neuroinflammation.
2. Neuroplasticity enhancement. The BDNF increase mentioned earlier supports formation of new neural connections, which is how most antidepressants are thought to work.
3. Metabolic improvement. Insulin resistance and glucose dysregulation are linked to depression risk. Improving metabolic health may improve mood independently of weight loss.

This research is early-stage. GLP-1 agonists are not approved for depression treatment, and the trials are small. But the signal is consistent across multiple studies: if anything, these medications appear to protect against depression rather than cause it.

The paradox remains: if the pharmacology is potentially antidepressant, why do some individual patients feel worse? The answer, again, appears to be the psychological adaptation to rapid weight loss rather than the direct drug effect.

When to call your provider

Within 24 to 48 hours:

• Mood symptoms lasting more than 2 weeks at a stable dose
• New onset of symptoms after several months on a stable dose without recent life stressors
• Symptoms interfering with work, relationships, or daily function
• Worsening of pre-existing depression despite stable psychiatric medication
• Anxiety severe enough to cause avoidance behavior or panic attacks

Same day:

• Suicidal thoughts (even without plan or intent)
• Severe hopelessness or thoughts that life isn't worth living
• Self-harm urges
• Inability to get out of bed or complete basic self-care for more than 2 days

Emergency care:

• Active suicidal plan or intent
• Self-harm behavior
• Psychotic symptoms (hallucinations, delusions)
• Severe agitation or inability to ensure your own safety

The threshold for calling is lower if you have a history of depression, bipolar disorder, or other psychiatric conditions. Don't wait to see if symptoms resolve on their own if they're interfering with function.

FAQ

Does Mounjaro cause depression? No. Clinical trial data from over 6,500 patients shows no statistically significant increase in depression rates compared to placebo. Depression occurred in 1.8% of tirzepatide patients and 1.9% of placebo patients in the SURMOUNT-1 trial.

Can Mounjaro make existing depression worse? For most patients, no. Subgroup analysis of patients with baseline depression showed stable or slightly improved depression scores over 72 weeks. However, individual responses vary, and close monitoring is recommended if you have pre-existing depression.

Why do some people report feeling depressed on Mounjaro? Mood changes during GLP-1 therapy are usually related to the rapid weight loss process (identity disruption, social changes, loss of food as coping mechanism) rather than direct drug effects. Fatigue and irritability from side effects can also be misinterpreted as depression.

Should I stop Mounjaro if I feel depressed? Not without consulting your provider. Many cases of low mood during treatment are transient and respond to dose adjustment, nutritional optimization, or psychological support. Your provider can help determine whether the medication is contributing and whether discontinuation is necessary.

Can I take antidepressants with Mounjaro? Yes. There are no known drug interactions between tirzepatide and SSRIs, SNRIs, or other common antidepressants. The medications can be taken together safely. Some patients report slightly worse nausea during the first 2 weeks if combining with an SSRI.

Does compounded tirzepatide have the same depression risk as brand-name Mounjaro? Yes. Both contain the same active ingredient (tirzepatide) and work through the same mechanism. The psychiatric profile is comparable. Compounded versions are not FDA-approved and have not undergone the same clinical trial process, but the pharmacology is identical.

How long do mood changes last on Mounjaro? Most mood-related symptoms during GLP-1 therapy are transient and improve within 2 to 4 weeks at a stable dose. If symptoms persist beyond 2 weeks or worsen over time, evaluation is warranted to determine if they're related to the medication or another cause.

Is depression more common at higher Mounjaro doses? No clear dose-response relationship exists in the clinical trial data. Depression rates were similar across 5 mg, 10 mg, and 15 mg doses in the SURMOUNT trials (range 1.6% to 2.2% across all doses).

Can rapid weight loss cause depression even if the medication doesn't? Yes. Studies of bariatric surgery patients show 7% to 12% develop new-onset depression in the first year post-surgery despite successful weight loss. The psychological adaptation to rapid body change is demanding and can destabilize mood in vulnerable individuals.

Will Mounjaro help my depression? Emerging research suggests GLP-1 agonists may have antidepressant properties, but they are not approved for depression treatment. If you have depression, continue working with a mental health provider. Don't rely on Mounjaro as depression treatment.

What's the difference between feeling tired and feeling depressed on Mounjaro? Fatigue is a common side effect during titration and usually improves within 2 to 3 weeks at a stable dose. Depression involves persistent low mood, loss of interest in activities, feelings of worthlessness, and other symptoms beyond just tiredness. If you're unsure, use a screening tool like the PHQ-9 or consult your provider.

Should I avoid Mounjaro if I have a history of depression? Not necessarily. Pre-existing depression was not an exclusion criterion in clinical trials, and patients with depression history had similar outcomes. However, your depression should be stable and well-managed before starting treatment, and closer monitoring during titration is recommended.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. Diabetes Obesity and Metabolism. 2023.
3. Dawes AJ et al. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery. JAMA Surgery. 2016.
4. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Obesity. 2023.
5. Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. Reviews in the Neurosciences. 2014.
6. Dickson SL et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food. Neuropsychopharmacology. 2012.
7. Femminella GD et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease. Frontiers in Neuroscience. 2019.
8. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. Lancet Diabetes & Endocrinology. 2022.
9. SAMHSA. National Survey on Drug Use and Health. 2022.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Gault VA et al. GIP(3-30)NH2 is an antagonist of the GIP receptor and demonstrates GIP- and GLP-1-like actions in obese diabetic (ob/ob) mice. Behavioural Brain Research. 2015.
12. Wang W et al. Association of GLP-1 receptor agonist use with risk of depression and suicidal ideation. Nature Medicine. 2023.
13. Mansur RB et al. Liraglutide for treatment-resistant depression: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry. 2024.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.